Cefixime : A pharmacoeconomic perspective.
Cefixime, the first oral third-generation cephalosporin available, is commonly used for the treatment of upper and lower respiratory tract infections, otitis media, sinusitis, urinary tract infections, and gonorrhea.
The drug has a number of characteristics that make it effective when administered once or twice daily : a half-life of 3 to 4 hours, activity against most common pathogens involved in the infections for which it is indicated, and serum and interstitial concentrations greater than the minimum inhibitory concentration of most of the common pathogens of these infections for up to 24 hours after a 400-mg dose.
In a meta-analysis of both clinical and postmarketing studies, short-course therapy with cefixime has been shown to be as effective as other drugs (eg, ofloxacin and amoxicillin) often used for the treatment of respiratory infections, cystitis, and gonorrhea.
In the treatment of community-acquired pneumonia, cefixime has been shown to be effective in transitional therapy, whereby clinically stable patients are converted from parenteral third-generation cephalosporins to this agent, resulting in the reduction of both direct and indirect costs.
In the current health care environment in many countries, another advantage of short course or transitional therapy with cefixime is the resulting reduction in both direct and indirect costs.
Mots-clés Pascal : Céfixime, Pneumonie, Otite moyenne, Sinusite, Cystite, Gonococcie, Bactériose, Infection, Voie orale, Chimiothérapie, Traitement, Homme, Analyse coût, Economie santé, Article synthèse, Céphalosporine dérivé, Antibiotique, Antibactérien, Appareil respiratoire pathologie, Poumon pathologie, ORL pathologie, Oreille moyenne pathologie, Appareil urinaire pathologie, Vessie pathologie, Voie urinaire pathologie, Appareil génital pathologie
Mots-clés Pascal anglais : Cefixime, Pneumonia, Otitis media, Sinusitis, Cystitis, Gonococcal infection, Bacteriosis, Infection, Oral administration, Chemotherapy, Treatment, Human, Cost analysis, Health economy, Review, Cephalosporin derivatives, Antibiotic, Antibacterial agent, Respiratory disease, Lung disease, ENT disease, Middle ear disease, Urinary system disease, Bladder disease, Urinary tract disease, Genital diseases
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0127288
Code Inist : 002B02S02. Création : 21/05/1997.